Home > Journals > Minerva Urology and Nephrology > Past Issues > Minerva Urologica e Nefrologica 2010 December;62(4) > Minerva Urologica e Nefrologica 2010 December;62(4):377-86

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Share

 

REVIEWS   

Minerva Urologica e Nefrologica 2010 December;62(4):377-86

Copyright © 2010 EDIZIONI MINERVA MEDICA

language: English

Bladder cancer: a review of clinical management and prognostic factors

Patel T., Pitman M., Mckiernan J. M.

Department of Urology, Columbia University College of Physicians and Surgeons, New York, NY, USA


PDF


Bladder cancer is a heterogeneous disease that offers a unique challenge for the patient and the physician as treatment paradigms are continually evolving. There are multiple factors that can influence how each individual is treated, including lymphovascular invasion, micropapillary histology, and p53 nuclear accumulation which have demonstrated a worse prognosis in patients with bladder cancer. They can influence the use of neoadjuvant and adjuvant chemotherapy, which in itself can affect the timing of extirpative surgery. This review will focus on the contemporary management and treatment of bladder cancer focusing on areas of clinical decision making.

top of page